Evidence map›Paper›PMID 34787784›Full record

ArticleCurrent medical science2021

Cyr61 Alleviates Cholangitis by Inhibiting Cytotoxic Effects of CD8

Tiao-Chun Cheng, Han Li, Xi Luo, Lin-Ling Ju, Lin Chen, Jian-Guo Shao, Yong-Jun She, Min Li, Zhao-Lian Bian

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tiao-Chun Cheng *Medical School of Nantong University, Nantong, 226006, China.
Han Li *Medical School of Nantong University, Nantong, 226006, China.
Xi LuoNantong Institute of Liver Disease, Nantong Third People's Hospital Nantong University, Nantong, 226006, China.
Lin-Ling JuNantong Institute of Liver Disease, Nantong Third People's Hospital Nantong University, Nantong, 226006, China.
Lin ChenNantong Institute of Liver Disease, Nantong Third People's Hospital Nantong University, Nantong, 226006, China.
Jian-Guo ShaoDepartment of Gastroenterology and Hepatology, Nantong Third People's Hospital, Nantong University, Nantong, 226006, China.
Yong-Jun SheDepartment of Anesthesiology, Nantong Third People's Hospital, Nantong University, Nantong, 226006, China.
Min LiDepartment of Gastroenterology and Hepatology, Nantong Third People's Hospital, Nantong University, Nantong, 226006, China.
Zhao-Lian BianDepartment of Gastroenterology and Hepatology, Nantong Third People's Hospital, Nantong University, Nantong, 226006, China. bianzhaolian1998@163.com.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePrimary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease. In recent years, researchers have found that cysteine-rich angiogenic inducer 61 (Cyr61, also known as CCN1) has a potential role in reducing portal inflammation in patients with PBC. This study aimed to explore the relationship between Cyr61 and PBC to provide new ideas and an experimental basis for the clinical treatment of PBC.

methodsAfter induction of the overexpression of Cyr61 in a mouse model of PBC using recombinant adenovirus, hematoxylin and eosin staining and pathological scores were used to indicate intrahepatic inflammation and bile duct damage. Real-time PCR was used to detect changes in inflammation-related cytokines in the liver. To further study the mechanism, we assessed whether Cyr61 protects bile duct epithelial cells from cytotoxic effects.

resultsSerum and hepatic Cyr61 levels were increased in the murine model of PBC. Overexpression of Cyr61 alleviated hepatic inflammation and bile duct injury in vivo. Cyr61 inhibited the cytotoxic effects of CD8

conclusionOur results provide novel insight into the pathogenesis of PBC and suggest that Cyr61 plays a dominant role in the cytotoxic effects on BECs in PBC. Consequently, therapeutic strategies targeting Cyr61 could be a potent therapy for PBC.

Indexed as

Cysteine-Rich Protein 61AnimalsBile DuctsCD8-Positive T-LymphocytesCytokinesDisease Models, AnimalEpithelial CellsInflammation MediatorsLiverLiver Cirrhosis, BiliaryMiceCCN1 protein, mouseCysteine-Rich Protein 61CytokinesInflammation Mediatorsbile duct damagecysteine-rich angiogenic inducer 61cytotoxicityinflammationprimary biliary cholangitis

Identifiers

PMID34787784
OpenAlexW3211494666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.